Developing an Oncology Workforce for the 21st Century

项目总结/摘要 芝加哥大学保罗·卡拉布雷西职业发展奖临床双轨制的总体目标 肿瘤学是为了增加高技能的临床医生（医学博士，D.O，s，药学博士，护士博士或 同等学历）和非临床博士后研究人员谁是能够设计和测试创新 在临床试验环境中假设驱动的临床治疗研究方案（试点/I期、II期和 III期试验）。为了做到这一点，我们已经创建了一个结构紧凑，指导教育计划内， 学术严谨的培训环境，准备最引人注目的高级研究员或初级教师在 临床肿瘤学在以病人为导向的研究事业。该计划是锚定在我们的综合 癌症中心和领导的Olufunmilayo Olopade，医学博士沿着与沃尔特Stadler，医学博士的大力支持， 执行委员会以及内部和外部咨询委员会。78篇研究训练 教师导师有国家卫生研究院或同等同行评审的资金，互动的一些合作 研究和培训工作，并有资格担任潜在的导师，每年为五名学员 参与K12计划。每名受训人员的任期至少为两年。在这次更新中， 应用，我们将继续在临床药理学，基因组学和 免疫治疗，同时增加临床信息学，数据科学等新兴领域的培训机会 和微生物组研究。保罗卡拉布雷西K12学者计划是我们的高度指导，说教 课程密集型计划，以及“动手”临床研究培训，导致科学硕士学位， 临床研究。利用芝加哥大学医学院的临床研究基础设施，我们 我还创建了一套灵活的综合跨学科课程，在翻译科学，融合 癌症基因组学、免疫学、药物基因组学和社区临床试验 网络自2010年以来完成该计划的18名学员中，有13名（72%）目前在学术 职业，其中7人（54%）担任副教授一级的任命。此外，这18名学员 共发表了176篇肿瘤学研究论文，是以下研究的主要研究者或合作研究者： 56项肿瘤学研究奖。重要的是，在过去的14年中， 供资周期的主要受益者是妇女或得不到充分服务的少数群体成员。保罗明确的目标是 卡拉布雷西学者计划，与我们机构的所有培训计划一样，其培训机会 而受益的将远远超出相对少数的学者，他们将获得奖学金。程序 已经产生了变革性的全球影响，并正在进入更大的肿瘤学实习生社区， 芝加哥和其他国家的学员谁来我们的机构作为全球肿瘤学学者。因此，在本发明中， 从该计划的实施和生产力中获得的好处是巨大的， 增加进行癌症临床试验的高技能临床医生和非临床医生的数量。

PROJECT SUMMARY/ABSTRACT The overall goal of the dual-track University of Chicago Paul Calabresi Career Development Award for Clinical Oncology is to increase the number of highly skilled clinicians (M.D.s, D.O,s, Pharm.D., nurses with PhD or equivalent) and non-clinician postdoctoral researchers who are capable of designing and testing innovative hypothesis-driven clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II and Phase III trials). To do this, we have created a tightly structured and mentored education program within an academically rigorous training environment that prepares the most compelling senior fellows or junior faculty in clinical oncology for careers in patient oriented research. The program is anchored within our Comprehensive Cancer Center and led by Olufunmilayo Olopade, MD along with Walter Stadler, MD with strong support from an Executive Committee as well as Internal and External Advisory Committees. The 78 research training faculty preceptors have NIH or equivalent peer- reviewed funding, interact on a number of collaborative research and training efforts and are well qualified to serve as potential mentors for the five trainees per year participating in this K12 program. Each trainee is appointed for a minimum of two years. In this renewal application, we shall continue successful elements of the program in clinical pharmacology, genomics and immunotherapy while enhancing training opportunities in emerging fields of clinical informatics, data science and microbiome research. The Paul Calabresi K12 Scholars Program is our highly mentored, didactic coursework-intensive program, and “hands on” clinical research training which results in a Master of Science in Clinical Investigation. Leveraging clinical research infrastructure across University of Chicago Medicine, we have also created a flexible set of integrated interdisciplinary courses in translational science that blends entrepreneurships, cancer genomics, immunology, pharmacogenomics and community based clinical trials network. Of the 18 trainees who have completed the program since 2010, 13 (72%) are currently in academic careers, of whom 7 (54%) hold appointments at the Associate Professor level. Moreover, these 18 trainees have published a total of 176 oncology research papers, and are Principal Investigators or Co-Investigators on 56 oncology research grant awards. Of significance, 7 of 14 (50%) appointments to the program in the last funding cycle were women or members of underserved minority groups. An explicit goal of this Paul Calabresi Scholars program, as with all training programs in our institution, is that its training opportunities and benefits will extend far beyond the relatively few scholars whose stipends it will provide. The program has had a transformative and global impact and is reaching into the larger oncology trainee community in Chicago and to trainees in other countries who come to our Institution as Global Oncology Scholars. Thus, the benefit that accrues from the program's implementation and productivity is substantial and will increase the number of highly skilled clinicians and non-clinicians conducting cancer clinical trials.